Talawar Therapeutics 与 Jatt II Acquisition Corp. 已就一项最终业务合并协议达成一致，此举旨在共同组建一家公开上市的创新型生物技术公司。新公司的核心战略将聚焦于开发针对炎症与免疫性疾病（I&I）的潜在“同类最佳”双特异性抗体疗法。
通过本次合并，新实体将获得公开市场平台，加速其前沿双抗药物的研发与商业化进程。该交易标志着两家公司在推动下一代免疫疗法方面的重大联合，旨在为患者提供更具创新性与有效性的治疗选择。
Talawar Therapeutics 与 Jatt II Acquisition Corp. 已就一项最终业务合并协议达成一致，此举旨在共同组建一家公开上市的创新型生物技术公司。新公司的核心战略将聚焦于开发针对炎症与免疫性疾病（I&I）的潜在“同类最佳”双特异性抗体疗法。
通过本次合并，新实体将获得公开市场平台，加速其前沿双抗药物的研发与商业化进程。该交易标志着两家公司在推动下一代免疫疗法方面的重大联合，旨在为患者提供更具创新性与有效性的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.